Should ACE inhibitors or ARBs be stopped if estimated glomerular filtration rate falls below 30 mL/min/1.73 m²?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

No, Do Not Stop ACE/ARB When GFR Falls Below 30

You should continue ACE inhibitors or ARBs even when eGFR falls below 30 mL/min/1.73 m², unless specific contraindications develop. 1

Guideline-Based Recommendation

The 2024 KDIGO guidelines explicitly state in Practice Point 3.6.7: "Continue ACEi or ARB in people with CKD even when the eGFR falls below 30 ml/min per 1.73 m²." 1 This represents the most current, authoritative guidance on this question and should direct clinical practice.

When to Consider Stopping (Limited Circumstances)

The KDIGO guidelines specify you should only consider reducing dose or discontinuing ACE/ARB in these specific situations 1:

  • Symptomatic hypotension that cannot be managed otherwise
  • Uncontrolled hyperkalemia despite medical treatment (not just elevated potassium—it must be refractory to management)
  • To reduce uremic symptoms when treating kidney failure at eGFR <15 mL/min/1.73 m²
  • Serum creatinine rises >30% within 4 weeks of initiation or dose increase

Supporting Evidence for Continuation

Multiple high-quality observational studies support continuing therapy:

Cardiovascular and mortality benefits: A 2021 Swedish nationwide study of 10,254 patients found that stopping RAS inhibitors at eGFR <30 was associated with 13.6 additional deaths per 100 patients and 11.9 additional major adverse cardiovascular events per 100 patients over 5 years. 2

Diabetic CKD outcomes: A 2023 prospective cohort of 10,400 patients with type 2 diabetes and advanced CKD showed discontinuation was associated with increased risk of MACE (HR 1.27), heart failure (HR 1.85), and ESKD (HR 1.30), with no increased risk of hyperkalemia. 3

ACE inhibitors vs ARBs: The 2024 STOP-ACEi trial found that discontinuing ACE inhibitors specifically led to worse outcomes—65% vs 54% reached kidney failure/KRT when stopped vs continued (HR 1.52). ARB discontinuation showed less clear harm. 4 However, the trial wasn't powered to compare agents directly.

Common Pitfall to Avoid

Do not reflexively stop these medications at an arbitrary eGFR threshold. The outdated practice of discontinuing at eGFR <30 likely stems from concerns about hyperkalemia and acute kidney injury, but the evidence shows the cardiovascular and renal benefits outweigh these risks when properly monitored. 1, 3, 2

Practical Management Algorithm

  1. Monitor closely (check potassium, creatinine within 2-4 weeks of any dose change) 1
  2. Manage hyperkalemia medically first with dietary restriction, diuretics, potassium binders—don't immediately stop the RAS inhibitor 1
  3. Accept modest creatinine increases up to 30% within 4 weeks 1
  4. Continue through dialysis initiation unless uremic symptoms require discontinuation 1

The evidence consistently demonstrates that continuing ACE/ARB therapy in advanced CKD provides substantial cardiovascular protection and may delay dialysis, with manageable risks when appropriately monitored.

References

Related Questions

For a patient with chronic kidney disease stage 4 and an estimated GFR of 28 mL/min, what is the appropriate dose of Lyrica (pregabalin)?
Based on the provided audit report, please prepare a medico‑legal expert report evaluating whether the care given to a 61‑year‑old woman with type‑2 diabetes mellitus, systemic hypertension, dyslipidemia, chronic kidney disease (non‑dialysis), and critical‑stage peripheral arterial disease (Fontaine/Rutherford stage V) adhered to current guidelines and the standard of care, and determine if any negligence, imprudence, lack of skill, excess therapy, or omission of care occurred.
Are antihistamines safe for patients with chronic kidney disease (CKD), and how should dosing be adjusted based on estimated glomerular filtration rate (eGFR)?
What is the appropriate dosing and monitoring of bisoprolol for blood pressure control in a patient with stage 4 chronic kidney disease (eGFR 15–29 mL/min)?
What dietary recommendations should be followed for a patient with chronic kidney disease stage 3b (eGFR 30–44 mL/min/1.73 m²)?
What is the age‑based size chart for selecting Foley catheters?
How should a patient with a positive anti‑HCV antibody test be evaluated and managed?
What is the recommended regimen for vitamin D3 supplementation with calcium, and what are the contraindications?
In a patient with low total iron‑binding capacity, low red blood cell count, and normal‑high mean corpuscular hemoglobin, what is the most likely diagnosis and what further evaluation should be performed?
Does Trulicity (dulaglutide) cause gastroparesis?
Does lying on an electric blanket increase urinary frequency?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.